Century Timeline | Steady Lantern 53

Four intervals, one uneven record

The documentary trail is not uniform. Colonial writing, laboratory publications, regulatory notices, and later treatment narratives answer different questions and deserve different levels of confidence.

Before 1900

Living traditions precede the written archive

Iboga’s use in Gabon and nearby parts of Central Africa is associated with Bwiti religious and healing traditions. Oral transmission, ritual practice, and local knowledge precede European scientific naming; outside records are not the origin of that history.

Descriptions of an unchanged “ancient practice” should be treated cautiously. Traditions change, communities differ, and many claims about exact antiquity or sequence are difficult to verify from primary sources. Cultural discussion needs more than a laboratory timeline, including the context explored in Bwiti and iboga traditions.

1901–1966

Botany, extraction, and a pharmaceutical chapter

In 1901, French botanist Henri Baillon described Tabernanthe iboga; early twentieth-century chemistry then isolated ibogaine from the plant. The familiar scientific record begins here, but it is only one strand of a much longer cultural history.

Mid-century France saw ibogaine sold in a stimulant preparation known as Lambarène. Its commercial presence is a historical fact, not evidence of contemporary safety or efficacy. For a broad overview of the compound’s identification and later interest, the ibogaine reference history is useful as a starting point, while original papers remain more probative for individual dates.

1967–2000

Drug scheduling and informal treatment networks

Howard Lotsof’s later accounts place a personal observation about opioid withdrawal in 1962; accounts of that episode are retrospective and should not be confused with a controlled clinical finding. U.S. patents followed in the 1980s, while underground and international treatment activity expanded unevenly.

In 1967, ibogaine entered U.S. federal scheduling. The DEA controlled-substances schedule records ibogaine among Schedule I substances in the United States. Scheduling shaped access and research conditions, but it does not itself resolve questions of therapeutic value.

2001–5 October 2026

Research interest alongside unresolved risk

Twenty-first-century work has included observational reports, pharmacology studies, safety discussions, and limited clinical investigation. These records offer signals and questions, not a settled clinical verdict. No broad conclusion should turn small samples, self-selection, or short follow-up into proof.

Interest has also traveled through public narratives about trauma, sports, and substance use. Those routes should be read against the fuller discussion of claimed benefits, with attention to what the evidence does and does not establish.

Landscape view accompanying a century-long account of ibogaine history — Historical chronology is clearest when it separates plant knowledge, chemical research, public policy, and later treatment narratives.

A closer reading

Key turns need context, not a straight line

Early botanical description made the plant legible to European science; alkaloid isolation made it available for pharmacological study. Neither event displaced the cultural setting from which iboga was known. In a timeline, the difference between discovery by a field and recognition by that field matters.

By the late twentieth century, public attention increasingly centered on opioid withdrawal and later on other conditions. Accounts involving boxers and ibogaine narratives illustrate how prominent individual stories can circulate faster than durable clinical evidence. The historical record should retain both the account and the uncertainty around what it can demonstrate.

“A date is not a conclusion.” It can locate a document, a regulatory decision, a published observation, or a remembered event—but it cannot settle causation, safety, or cultural meaning on its own.

For a wider map of the evidence questions that sit behind this chronology, the site’s research landscape keeps study design, measurement, and unanswered questions in view.

Annotated record: studies, rules, and institutions

Open each note for the kind of source it represents and the limits that should travel with it. This is an orientation to the record, not medical or legal guidance.

1901 — botanical description and early chemical work

Baillon’s formal botanical description belongs to the colonial-era scientific archive. Subsequent early twentieth-century reports on ibogaine isolation established a chemical object for laboratory study. Dates are comparatively stable; the broader cultural framing in those records is limited and often shaped by colonial sources.

The U.S. National Library of Medicine’s PubMed research archive is useful for locating later indexed biomedical literature, though it does not substitute for reading a study’s design and limitations.

1960s–1980s — early treatment claims and patents

Lotsof’s accounts and subsequent patents are influential in the modern treatment narrative. They document an effort to frame ibogaine as relevant to substance dependence, but patents and testimonial accounts are not randomized clinical trials. Historical importance and evidentiary strength are separate questions.

People looking for a grounded chronology of trauma-related claims can compare this distinction with the material on ibogaine and PTSD, where lived experience, clinical language, and established evidence need to remain separate.

1990s — formal research interest, constrained by safety and regulation

Government-supported planning and early clinical development brought ibogaine into a more formal U.S. research conversation in the 1990s. That trajectory did not produce broad approval. Historical summaries sometimes compress this period into a single abandoned trial narrative; primary documents and dated reports are preferable where available.

The Food and Drug Administration explains that drug development and approval requires a defined evidentiary process; public interest or historical use is not the same as approval.

2000s–2026 — international practice, observational literature, and ongoing scrutiny

As treatment activity continued outside the United States, much of the literature remained observational, retrospective, or limited in size. Such work may describe outcomes and adverse events, but it cannot on its own answer every causal or comparative question. Reports of cardiac risk and deaths underscore why historical interest must not be framed as a safety endorsement.

Questions about contemporary offerings, including accounts associated with ibogaine treatment in Arizona, are best approached through legal status, screening claims, emergency capacity, independent oversight, and transparent evidence—not marketing language. Financial narratives have also emerged around ibogaine-related stock activity, which should not be mistaken for clinical validation.

How to use a historical timeline carefully

A credible chronology shows its seams: where a primary source exists, where a claim is repeated secondhand, and where research language exceeds what a study can bear.

Primary record

What can be dated

Taxonomic publications, patents, journal articles, and formal scheduling actions can often be anchored to documents, even when interpretation remains open.

Contested account

What should be marked

Retrospective origin stories, informal treatment claims, and simple accounts of cultural practice need attribution, uncertainty, and room for correction.

Clinical boundary

What history cannot prove

Longstanding use, a compelling anecdote, or an observational report does not establish safety, dosing, effectiveness, or suitability for any person.

Keep the frame

History is a beginning, not a treatment decision.

For an evidence-first overview of why this resource separates preliminary signals from established findings, visit Steady Lantern 53’s main guide. The site’s method and independence notes explain the standards behind that approach.

Review safety context